Clinical Trial Update: 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports results from a Phase 1 study evaluating the combination of Lutetium-177-PSMA-617 and pembrolizumab in patients with metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-02-25